iX Biopharma has high hopes for drug spin-off

CATALIST-LISTED iX Biopharma wishes investors would focus less on its current topline or bottom-line, and more on the potential of its products and patented technology.

This search for understanding investors is one reason it is looking to spin off its pharmaceutical and medicinal cannabis business for a listing in Hong Kong, said director of corporate affairs Yee Chia Hsing.

"The type of conversation that they have (in Hong Kong) is very different. They don't ask you about when you turn profitable ... They talk about your drug pipeline, they try to understand the size of the market."